Skip to content
sellWeak10b5-1 plan

Alane P Barnes sold $1.2M of BCRX

Chief Legal Officer at BIOCRYST PHARMACEUTICALS INC. 161,680 shares at an average of $7.21, traded Dec 1, 2025, filed Dec 3, 2025.

Warning score
15
Value
$1.2M
161,680 shares
Holdings after
345,476
-32% from before
From 52-week low
+11%
low $6.41, close $7.13
From 52-week high
-36%
high $11.19, as of Dec 1, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 32% of holdings
    +10
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -4.5%, 3m +9.2%, 6m +5.1%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BCRXOct 13, 2026 · close 8.07
Since filing Dec 3, 2025: +2.8%SPY +15.0% · excess -12.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000882796-25-000027, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 1, 2025MOption exercise
Common Stock10b5-1
+91,004$3.22$293k507,156Dec 3, 2025
Dec 1, 2025SOpen-market sale
Common Stock10b5-1
-91,004$7.10$647k416,152Dec 3, 2025
Dec 2, 2025SOpen-market sale
Common Stock10b5-1
-50,906$7.21$367k365,246Dec 3, 2025
Dec 3, 2025SOpen-market sale
Common Stock10b5-1
-19,770$7.65$151k345,476Dec 3, 2025
Dec 1, 2025MOption exercise
Emp. Stock Option (Right to Buy)derivative10b5-1
-91,004$0.00$00Dec 3, 2025

Related signals

Other insiders at BIOCRYST PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
BCRXsell 2
BIOCRYST PHARMACEUTICALS INC
Amy E McKee
director
$100k
11,180 shares
-26%
12Weak
BCRXsell 210b5-1
BIOCRYST PHARMACEUTICALS INC
Alane P Barnes
Chief Legal Officer
$596k
62,500 shares
-13%
36Weak
BCRXsell 2
BIOCRYST PHARMACEUTICALS INC
Theresa Heggie
director
$505k
49,933 shares
-43%
23Weak
BCRXsell 210b5-1
BIOCRYST PHARMACEUTICALS INC
Alane P Barnes
Chief Legal Officer
$1.4M
150,000 shares
-27%
6Weak
BCRXsell10b5-1
BIOCRYST PHARMACEUTICALS INC
Alane P Barnes
Chief Legal Officer
$167k
21,773 shares
-5%
6Weak
BCRXsell10b5-1
BIOCRYST PHARMACEUTICALS INC
Alane P Barnes
Chief Legal Officer
$162k
21,210 shares
-6%
8Weak
BCRXsell10b5-1
BIOCRYST PHARMACEUTICALS INC
Machelle Sanders
director
$69k
9,600 shares
-24%
39Weak
BCRXsell
BIOCRYST PHARMACEUTICALS INC
Theresa Heggie
director
$596k
70,000 shares
-52%
2Weak
BCRXsell10b5-1
BIOCRYST PHARMACEUTICALS INC
Nancy J Hutson
director
$53k
7,000 shares
-7%
42Moderate
BCRXsell 3
BIOCRYST PHARMACEUTICALS INC
Amy E McKee
director
$54k
8,600 shares
-24%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.